戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 curs bound to the membrane glycoprotein CD26/dipeptidyl peptidase IV.
2  complex with the cell membrane protein CD26/dipeptidyl peptidase IV.
3 gelatinase that is related to the ectoenzyme dipeptidyl peptidase IV.
4 xopeptidases prolylcarboxypeptidase and CD26/dipeptidyl peptidase IV.
5 lymphocytes in a process independent of CD26/dipeptidyl peptidase IV.
6 n in syngeneic Fischer 344 rats deficient in dipeptidyl peptidase IV.
7 r repopulation by histochemical staining for dipeptidyl peptidase IV.
8 ll surface multifunctional glycoprotein CD26/dipeptidyl peptidase IV.
9  in juvenile and senescent rats deficient in dipeptidyl-peptidase IV.
10 -glucosidase (37.8%), alpha-amylase (35.6%), dipeptidyl peptidase-IV (34.4%), reactive oxygen species
11 heir juices, and the enzymatic inhibition of dipeptidyl peptidase-IV, a-amylase, a-glucosidase, nitri
12 a leukocyte activation marker that possesses dipeptidyl peptidase IV activity but whose natural subst
13 ified as a soluble human plasma protein with dipeptidyl peptidase IV activity that is expressed and r
14 n known to bind adenosine deaminase and have dipeptidyl peptidase IV activity.
15 border membrane vesicles reveals that it has dipeptidyl peptidase IV activity.
16  hepatocyte colonies with strong canalicular dipeptidyl peptidase IV activity.
17 ity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymati
18 tivities, among them primarily inhibition of dipeptidyl peptidase IV and angiotensin-converting enzym
19  atrophy and marked up-regulation of mucosal dipeptidyl peptidase IV and PepT1 messenger RNA.
20 tology and expression of brush border enzyme dipeptidyl peptidase IV and peptide transporter PepT1 me
21 s are a good source of natural inhibitors of dipeptidyl peptidase-IV and prolyl endopeptidase and cou
22 th expression of the brush border hydrolases dipeptidyl-peptidase IV and sucrase-isomaltase or with b
23 ent on degradation by neutral endopeptidase, dipeptidyl peptidase IV, and aminopeptidase P.
24 f, its mRNA, and the "NPY-converting enzyme" dipeptidyl peptidase IV (both protein and mRNA), which t
25 an unusual substrate specificity shared with dipeptidyl peptidase IV (CD26/DPPIV).
26 l specificity that is comparable to both the dipeptidyl-peptidase IV/CD26 and lactococcal x-prolyl di
27                  Three groups of mutant F344 dipeptidyl peptidase IV-deficient (DPPIV(-)) rats were r
28 integrate into the liver parenchyma, we used dipeptidyl peptidase IV-deficient F344 rats as hosts.
29 sed transplanted hepatocytes as reporters in dipeptidyl peptidase IV-deficient F344 rats.
30 eficient rats, which allowed localization of dipeptidyl peptidase IV-deficient hepatocytes in normal
31 , we used transplanted cells as reporters in dipeptidyl peptidase IV-deficient mice.
32 hepatocytes were transplanted into syngeneic dipeptidyl peptidase IV-deficient rats followed by histo
33                                       Use of dipeptidyl peptidase IV-deficient rats should help furth
34                                              Dipeptidyl peptidase IV-deficient rats were used as reci
35 atase (ATPase) activity in normal but not in dipeptidyl peptidase IV-deficient rats, which allowed lo
36  F344 rat hepatocytes with or without DAR in dipeptidyl peptidase IV-deficient rats.
37 ter transplanting syngeneic hepatocytes into dipeptidyl peptidase IV-deficient rats.
38 t and proliferation of transplanted cells in dipeptidyl peptidase IV-deficient rats.
39 hepatocytes were transplanted into syngeneic dipeptidyl peptidase IV-deficient rats.
40 d Fischer 344 rat hepatocytes into syngeneic dipeptidyl peptidase IV-deficient rats.
41                                              Dipeptidyl-peptidase-IV-deficient female rats received B
42  both analogues were completely resistant to dipeptidyl peptidase IV degradation.
43 ts but does not inhibit close FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and pro
44                                      CD26 or dipeptidyl peptidase IV (DP IV) is expressed on various
45                                              Dipeptidyl peptidase IV (DP-IV) is a cell surface serine
46                                              Dipeptidyl peptidase IV (DP-IV), a member of the prolyl
47 s in T cell activation, was shown to possess dipeptidyl peptidase IV (DPP IV) activity.
48  of multidrug therapies and the relevance of dipeptidyl peptidase IV (DPP IV) and carbonic anhydrases
49 6)PAL) and GIP(Lys(37)PAL) were resistant to dipeptidyl peptidase IV (DPP IV) degradation.
50                                              Dipeptidyl peptidase IV (DPP IV) expressed on rat lung c
51                                              Dipeptidyl peptidase IV (DPP IV) is a ubiquitous membran
52     Binding of plasminogen type II (Pg 2) to dipeptidyl peptidase IV (DPP IV) on the surface of the h
53  method to a variety of proteases, including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8
54 ained lactam aminoboronic acid inhibitors of dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5).
55 gorous steady state enzyme kinetic assay for dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5).
56 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of typ
57  novel aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV (DPP-4) inhibitor 1 has been dev
58 ered as potent, selective, and orally active dipeptidyl peptidase IV (DPP-4) inhibitors by extensive
59 les are rapidly inactivated by the action of dipeptidyl peptidase IV (DPP-4) which limits their use a
60 -terminal amino acids of these chemokines by Dipeptidyl Peptidase IV (DPP-4).
61                                              Dipeptidyl peptidase IV (DPP-IV) belongs to a family of
62                                              Dipeptidyl peptidase IV (DPP-IV) degrades the incretin h
63 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of ty
64 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of ty
65                                Inhibition of dipeptidyl peptidase IV (DPP-IV) has been proposed recen
66 agon-like peptide-1 (GLP-1) degrading enzyme dipeptidyl peptidase IV (DPP-IV) have been shown to be e
67                    Xanthine oxidase (XO) and dipeptidyl peptidase IV (DPP-IV) inhibition by amino aci
68                                              Dipeptidyl peptidase IV (DPP-IV) inhibition has the pote
69  acid linked l-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the i
70 ad angiotensin-I-converting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory activities,
71 tent angiotensin converting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory and oxygen r
72                                   Nine novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (FL
73 ts (DOE) was used to optimise the release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides dur
74 th subtilisin-trypsin-flavourzyme) to obtain dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.
75 of 72 dietary proteins to act as a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.
76                  Camel milk proteins contain dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.
77                                              Dipeptidyl peptidase IV (DPP-IV) is considered a key tar
78 as no significant effect of pH regulation on dipeptidyl peptidase IV (DPP-IV) properties.
79 These peptides are known to act as preferred dipeptidyl peptidase IV (DPP-IV) substrates.
80 l screening was performed against the target dipeptidyl peptidase IV (DPP-IV) to identify good chemic
81 on of a-amylase (AA), a-glucosidase (AG) and dipeptidyl peptidase IV (DPP-IV)) of bovine (BC) and cam
82 re deficient for the bile canalicular enzyme dipeptidyl peptidase IV (DPP-IV), cultured WB-F344 rat l
83 HSA), other components, such as the protease dipeptidyl peptidase IV (DPP-IV), possibly contribute to
84 N-terminal sequence-specific serine protease dipeptidyl peptidase IV (DPP-IV).
85                                              Dipeptidyl peptidase IV (DPP-IV; E.C. 3.4.14.5), a serin
86 ed a high frequency of the occurrence (A) of dipeptidyl peptidase-IV (DPP-IV) (0.62) and angiotensin
87 uggest a variety of bioactivities, including dipeptidyl peptidase-IV (DPP-IV) and angiotensin convert
88 wever, its rapid degradation by enzymes like dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptida
89 P-1 is short because of rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.
90 f GLP-1 is short due to rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.
91                                              Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised t
92 in-I converting enzyme (ACE) inhibition, and dipeptidyl peptidase-IV (DPP-IV) inhibitory activities.
93                                              Dipeptidyl peptidase-IV (DPP-IV) is a serine protease in
94 P-1, due to its resistance to degradation by dipeptidyl peptidase-IV (DPP-IV).
95 n, expression of sucrase isomaltase (SI) and dipeptidyl-peptidase IV (DPP-IV), two well known intesti
96 ies to a single transmembrane protein, CD26 (dipeptidyl peptidase IV [DPP IV]) (monoreactive anti-DPP
97                                              Dipeptidyl peptidase IV (DPP4) deactivates glucose-regul
98                                              Dipeptidyl peptidase IV (DPP4) inhibitors are emerging a
99                                              Dipeptidyl peptidase IV (DPP4/CD26) and seprase/fibrobla
100                      With papain hydrolysis, dipeptidyl peptidase-IV (DPP4) and angiotensin-convertin
101  to identify neonatal Fc receptor (FcRn) and dipeptidyl-peptidase IV (DPP4) as entry factors for HAst
102 ing of the purified protein identified it as dipeptidyl peptidase IV (DPPIV) (EC ), which was confirm
103                                              Dipeptidyl peptidase IV (DPPIV) activity was quantified
104 , we treated Fischer 344 (F344) rats lacking dipeptidyl peptidase IV (DPPIV) activity with cyclophosp
105 (r) 110,000 surface-bound ectopeptidase with dipeptidyl peptidase IV (DPPIV) activity, has an array o
106 epatocytes can give rise to SHPCs, rats with dipeptidyl peptidase IV (DPPIV) chimeric livers, which h
107 expression of CD26, especially its intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity, results
108  study demonstrates that the 175-kDa form of dipeptidyl peptidase IV (DPPIV) found in normal human se
109 ine (C5-Pro-Pro) analogues was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potentia
110                                              Dipeptidyl peptidase IV (DPPIV) is a cell surface peptid
111                                              Dipeptidyl peptidase IV (DPPIV) is a serine protease wit
112 as evaluated by injecting cell isolates from dipeptidyl peptidase IV (DPPIV) positive (DPPIV+) Fische
113 number of TIM4(+) RMs coincide with those of dipeptidyl peptidase IV (DPPIV)(+) FAPs, suggesting thei
114                                              Dipeptidyl peptidase IV (DPPIV), a cell surface serine p
115 ddresses the hypothesis that the activity of dipeptidyl peptidase IV (DPPIV), an enzyme that inactiva
116 expression of a cell transplantation marker, dipeptidyl peptidase IV (DPPIV), and GFP.
117 membrane-bound prolyl peptidases seprase and dipeptidyl peptidase IV (DPPIV), at invadopodia of migra
118 transplanted intrasplenically into syngeneic dipeptidyl peptidase IV (DPPIV)-deficient rats.
119                          FAPalpha exhibits a dipeptidyl peptidase IV (DPPIV)-like fold, featuring an
120 g the protocol of injecting hepatocytes from dipeptidyl peptidase IV (DPPIV)-positive donors into ret
121 ffects of HIR on engraftment of transplanted dipeptidyl peptidase IV (DPPIV)-positive hepatocytes in
122 howed similarities to the 110-kDa subunit of dipeptidyl peptidase IV (DPPIV).
123 their ability to inhibit the serine protease dipeptidyl peptidase IV (DPPIV).
124 rotein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV).
125 ed structure of AprA has similarity to human dipeptidyl peptidase IV (DPPIV).
126 y inhibition of the closely related protease dipeptidyl peptidase IV (DPPIV).
127  proteins after enzymatic digestion, against dipeptidyl peptidase IV (DPPIV); an enzyme known to deac
128 ied throughout a 6-month period in syngeneic dipeptidyl peptidase IV (DPPIV-) mutant F344 rats.
129                             Lung endothelial dipeptidyl peptidase IV (DPPIV/CD26) is a vascular addre
130 ate or propionate increased DBS, enhanced by dipeptidyl peptidase-IV (DPPIV) inhibition, at the same
131                                   Wild-type (dipeptidyl peptidase IV [DPPIV(+)]) embryonic day (ED) 1
132                                              Dipeptidyl peptidase IV (EC 3.4.14.5; DPP IV), also know
133 -Pro-naphthylamide in the presence of excess dipeptidyl-peptidase IV (EC 3.4.14.5).
134 h CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating t
135  110-kDa cell surface glycoprotein, exhibits dipeptidyl peptidase IV enzyme activity and plays an imp
136  assays based on F344 recipient rats lacking dipeptidyl peptidase IV enzyme activity to identify tran
137                    Markers for Y chromosome, dipeptidyl peptidase IV enzyme, and L21-6 antigen were u
138 ow cytometry and histochemical estimation of dipeptidyl-peptidase IV enzyme activity of donor cells i
139 ibited APCE with a K(i) of 54 microM but not dipeptidyl peptidase IV even at 2 mM.
140 lly marked hepatocytes (isolated from normal Dipeptidyl peptidase IV+ Fischer 344 rats) were delivere
141  5' upstream region (-448/-443) of the human dipeptidyl peptidase IV gene promoter containing a conse
142 imal inhibitory concentration, ~14.0 nM) and dipeptidyl peptidase-IV (half-maximal inhibitory concent
143                               Further, since dipeptidyl peptidase IV has an absolute requirement for
144  brush border Na(+)-H(+) exchanger NHE3 with dipeptidyl peptidase IV in the proximal tubule.
145 vivo, but this effect was only detected with dipeptidyl peptidase IV inhibition, while mucosal respon
146 ulocyte-colony stimulating factor (G-CSF), a dipeptidyl peptidase IV inhibitor (DPP-4i), and a proton
147                                          The dipeptidyl peptidase-IV inhibitor saxagliptin (Onglyza)
148 tivities and clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflamma
149  in medicinal chemistry applications such as dipeptidyl peptidase IV inhibitors.
150 rials investigating cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) among patien
151 d 1-beta-fructofuranosyl nystose) are potent dipeptidyl peptidase-IV inhibitors as well as peroxisome
152                                  The highest dipeptidyl peptidase IV inhibitory activity was obtained
153  CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV, is directly associated with ade
154 tal liver cells were transplanted into adult dipeptidyl peptidase IV knockout mice and differentiated
155 normal and retrorsine (Rs) treated syngeneic dipeptidyl peptidase IV mutant (DPPIV(-)) F344 rats.
156  cells) into the liver of retrorsine-treated Dipeptidyl peptidase IV- mutant Fischer 344 rats in conj
157                 One week post-MMC treatment, dipeptidyl peptidase IV negative host rats were given a
158 ction of several serine proteases, including dipeptidyl peptidase-IV, neutrophil elastase, matrix met
159  rats into syngeneic recipients deficient in dipeptidyl peptidase IV or from transgenic hepatitis B s
160  vivo and mature into hepatocytes expressing dipeptidyl peptidase IV or fumarylacetoacetate hydrolase
161             These data strongly suggest that dipeptidyl peptidase IV plays a role in the inactivation
162 ntained large clusters of sinusoids lined by dipeptidyl peptidase IV positive endothelial cells coexp
163  newborn, or adult total liver isolates from dipeptidyl peptidase IV positive rats.
164 otransfection of USF expression vectors with dipeptidyl peptidase IV promoter constructs revealed tha
165 nd possible site of USF interaction with the dipeptidyl peptidase IV promoter was localized to the -1
166              Interestingly, the product of a dipeptidyl peptidase IV substrate inactivated bile canal
167 ty against angiotensin converting enzyme and dipeptidyl peptidase IV when assessed using in silico to
168 ogenic substrate, Ala-Pro-2naphthylamide, by dipeptidyl peptidase IV, whereas d-Pro2-endomorphin-2 wa
169 he substrate requirements of the proteinase, dipeptidyl peptidase IV which removes dipeptides from th
170 nzymatic activity of molecules such as CD26 (dipeptidyl-peptidase IV), which may act by metabolizing

 
Page Top